NCT01333462 - Safety and Immunogenicity Study of Inactivated Nasal Influenza Vaccine NB-1008 | Biotech Hunter

Enrollment

199

Participants

Timeline

Start Date

March 31, 2009

Primary Completion Date

August 31, 2009

Study Completion Date

September 30, 2010

Conditions

Healthy Adult Volunteers

Interventions

BIOLOGICAL

NB-1008

NB-1008 is composed of Fluzone containing 4 micrograms (mcg) or 10 micrograms of strain-specific hemagglutinin (HA) and 5%, 10%, 15%, or 20% W805EC adjuvant.

OTHER

Control

The controls include PBS placebo control as well as Fluzone IN and IM active controls.

Trial Locations (1)

66219

Johnson County Clin-Trials, Lenexa